The company will use the new funds to advance its lead compound, the first-in-class inhibitor of RAD51-mediated DNA repair, CYT-0851, into phase 2 monotherapy trials in hematologic cancers and solid tumors, to initiate trials combining CYT-0851 with other cancer therapies, and to expand preclinical research to identify and advance additional novel cancer therapies.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

128 Spring St. Building A 510
Lexington, MA 02421
USA

Phone

(857) 285-4140

Website

www.cyteir.com

Email Address

[email protected]

Overview

DNA damage and genomic instability are hallmarks of cancer and autoimmune diseases. This makes the disease-causing cells highly sensitive to drugs that target specific DNA repair factors. This is termed synthetic lethality.

Profile

Social Media

Cyteir Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Markus Renschler

Chief Scientific Officer

Paul Secrist

Vice President

Jean-Marc Lapierre

Vice President

Thomas O'Shea

VP - Bus. Development

Andrew Gengos

VP - Operations

Susan Doleman

VP - R & D

Judson Englert

VP - R & D

Barbara Wan

Browse more venture capital transactions:

Prev: 2/12/2021: Ensoma venture capital transaction
Next: 2/12/2021: Intenseye venture capital transaction

Share this article

News on VC Transactions

Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary